Therese M. L. Andersson

Therese M. L. Andersson

Auto-generated profile, based on publicly available information

Therese M. L. Andersson

Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2019 in The Lancet Oncology
Verified
Journal Article
Open access
MAMelina Arnold
Melina Arnold
MRMark Rutherford
Mark Rutherford
ABAude Bardot
Aude Bardot
JFJacques Ferlay
Jacques Ferlay
TATherese M-L Andersson
Therese M-L Andersson
FBFreddie Bray
Freddie Bray
Population-based cancer survival estimates provide valuable insights into the effectiveness of cancer services and can reflect the prospects of cure. As part of the second phase of the International Cancer Benchmarking Partnership (ICBP), the Cancer Survival in High-Income Countries (SURVMARK-2) project aims to provide a comprehensive overview of cancer survival across seven high-income countries and a comparative assessment of corresponding incidence and mortality trends. In this longitudinal, population-based study, we collected patient-level data on 3·9 million patients with cancer from population-based cancer registries in 21 jurisdictions in seven countries (Australia, Canada, Denmark, Ireland, New Zealand, Norway, and the UK) for seven sites of cancer (oesophagus, stomach, colon, rectum, pancreas, lung, and ovary) diagnosed between 1995 and 2014, and followed up until Dec 31, 2015. We calculated age-standardised net survival at 1 year and 5 years after diagnosis by site, age group, and period of diagnosis. We mapped changes in incidence and mortality to changes in survival to assess progress in cancer control. In 19 eligible jurisdictions, 3 764 543 cases of cancer were eligible for inclusion in the study. In the 19 included jurisdictions, over 1995-2014, 1-year and 5-year net survival increased in each country across almost all cancer types, with, for example, 5-year rectal cancer survival increasing more than 13 percentage points in Denmark, Ireland, and the UK. For 2010-14, survival was generally higher in Australia, Canada, and Norway than in New Zealand, Denmark, Ireland, and the UK. Over the study period, larger survival improvements were observed for patients younger than 75 years at diagnosis than those aged 75 years and older, and notably for cancers with a poor prognosis (ie, oesophagus, stomach, pancreas, and lung). Progress in cancer control (ie, increased survival, decreased mortality and incidence) over the study period was evident for stomach, colon, lung (in males), and ovarian cancer. The joint evaluation of trends in incidence, mortality, and survival indicated progress in four of the seven studied cancers. Cancer survival continues to increase across high-income countries; however, international disparities persist. While truly valid comparisons require differences in registration practice, classification, and coding to be minimal, stage of disease at diagnosis, timely access to effective treatment, and the extent of comorbidity are likely the main determinants of patient outcomes. Future studies are needed to assess the impact of these factors to further our understanding of international disparities in cancer survival. Canadian Partnership Against Cancer; Cancer Council Victoria; Cancer Institute New South Wales; Cancer Research UK; Danish Cancer Society; National Cancer Registry Ireland; The Cancer Society of New Zealand; National Health Service England; Norwegian Cancer Society; Public Health Agency Northern Ireland, on behalf of the Northern Ireland Cancer Registry; The Scottish Government; Western Australia Department of Health; and Wales Cancer Network.

20 August 2016 in Journal of Clinical Oncology
Verified
Journal Article
Open access
HBHannah Bower
Hannah Bower
MBMagnus Björkholm
Magnus Björkholm
PDPaul W. Dickman
Paul W. Dickman
MHMartin Höglund
Martin Höglund
PLPaul C. Lambert
Paul C. Lambert
TATherese M.-L. Andersson
Therese M.-L. Andersson
Purpose: A dramatic improvement in the survival of patients with chronic myeloid leukemia (CML) occurred after the introduction of imatinib mesylate, the first tyrosine kinase inhibitor (TKI). We assessed how these changes affected the life expectancy of patients with CML and life-years lost as a result of CML between 1973 and 2013 in Sweden. Materials and Methods: Patients recorded as having CML in the Swedish Cancer Registry from 1973 to 2013 were included in the study and followed until death, censorship, or end of follow-up. The life expectancy and loss in expectation of life were predicted from a flexible parametric relative survival model. Results: A total of 2,662 patients with CML were diagnosed between 1973 and 2013. Vast improvements in the life expectancy of these patients were seen over the study period; larger improvements were seen in the youngest ages. The great improvements in life expectancy translated into great reductions in the loss in expectation of life. Patients of all ages diagnosed in 2013 will, on average, lose < 3 life-years as a result of CML. Conclusion: Imatinib mesylate and new TKIs along with allogeneic stem cell transplantation and other factors have contributed to the life expectancy in patients with CML approaching that of the general population today. This will be an important message to convey to patients to understand the impact of a CML diagnosis on their life. In addition, the increasing prevalence of patients with CML will have a great effect on future health care costs as long as continuous TKI treatment is required.

6 March 2018 in Annals of Internal Medicine
Verified
Journal Article
Closed access
MHMalin Hultcrantz
Malin Hultcrantz
MBMagnus Björkholm
Magnus Björkholm
PDPaul W. Dickman
Paul W. Dickman
OLOla Landgren
Ola Landgren
ÅDÅsa R. Derolf
Åsa R. Derolf
TATherese M.L. Andersson
Therese M.L. Andersson
Patients with myeloproliferative neoplasms (MPNs) have been reported to be at increased risk for thrombotic events, but no population-based study has estimated this excess risk compared with matche... Background: Patients with myeloproliferative neoplasms (MPNs) are reported to be at increased risk for thrombotic events. However, no population-based study has estimated this excess risk compared ...

1 September 2016 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
DLDonghao Lu
Donghao Lu
TATherese M. L. Andersson
Therese M. L. Andersson
KFKatja Fall
Katja Fall
CHChristina M. Hultman
Christina M. Hultman
KCKamila Czene
Kamila Czene
FFFang Fang
Fang Fang
Patients with cancer are known to have an increased risk of psychiatric symptoms and disorders,1 cardiovascular diseases,2 and suicide.3 Historically, severe comorbidities among patients with cancer have largely been attributed to the adverse effects of cancer treatments, the complex pathophysiology of the underlying malignancy, or simply the burden of living with a progressing and potentially fatal disease.4,5 Not only does living with cancer induce severe psychological stress, but being diagnosed as having a cancer is also highly stressful. Recently, greatly increased risks of suicide and cardiovascular events shortly after cancer diagnosis were reported among patients with cancer in different countries, across various cancer types, and among both young and adult patients.6-12 However, these reports likely only represent the tip of the iceberg for the enormous psychological turmoil related to a newly received cancer diagnosis.

20 August 2012 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MHMalin Hultcrantz
Malin Hultcrantz
SKSigurdur Yngvi Kristinsson
Sigurdur Yngvi Kristinsson
TATherese M.-L. Andersson
Therese M.-L. Andersson
OLOla Landgren
Ola Landgren
SESandra Eloranta
Sandra Eloranta
MBMagnus Björkholm
Magnus Björkholm
Purpose: Reported survival in patients with myeloproliferative neoplasms (MPNs) shows great variation. Patients with primary myelofibrosis (PMF) have substantially reduced life expectancy, whereas patients with polycythemia vera (PV) and essential thrombocythemia (ET) have moderately reduced survival in most, but not all, studies. We conducted a large population-based study to establish patterns of survival in more than 9,000 patients with MPNs. Patients and Methods: We identified 9,384 patients with MPNs (from the Swedish Cancer Register) diagnosed from 1973 to 2008 (divided into four calendar periods) with follow-up to 2009. Relative survival ratios (RSRs) and excess mortality rate ratios were computed as measures of survival. Results: Patient survival was considerably lower in all MPN subtypes compared with expected survival in the general population, reflected in 10-year RSRs of 0.64 (95% CI, 0.62 to 0.67) in patients with PV, 0.68 (95% CI, 0.64 to 0.71) in those with ET, and 0.21 (95% CI, 0.18 to 0.25) in those with PMF. Excess mortality was observed in patients with any MPN subtype during all four calendar periods (P < .001). Survival improved significantly over time (P < .001); however, the improvement was less pronounced after the year 2000 and was confined to patients with PV and ET. Conclusion: We found patients with any MPN subtype to have significantly reduced life expectancy compared with the general population. The improvement over time is most likely explained by better overall clinical management of patients with MPN. The decreased life expectancy even in the most recent calendar period emphasizes the need for new treatment options for these patients.

1 September 2009 in Obstetrics & Gynecology
Verified
Journal Article
Closed access
TATherese M.-L. Msc Andersson
Therese M.-L. Msc Andersson
AJAnna L. V. Msc Johansson
Anna L. V. Msc Johansson
CHChung-Cheng ScD Hsieh
Chung-Cheng ScD Hsieh
SCSven Cnattingius
Sven Cnattingius
MLMats Lambe
Mats Lambe
OBJECTIVE: To estimate the incidence of pregnancy-associated breast cancer during different calendar periods and when pregnancy-associated breast cancer was diagnosed in relation to delivery. METHODS: This was a population-based cohort study using data from Swedish registers between 1963 and 2002, encompassing women aged 15–44 years at the date of breast cancer diagnosis. Outcome measures included incidence of pregnancy-associated breast cancer per 100,000 deliveries, the proportion of pregnancy-associated breast cancer among all breast cancers, and observed-to-expected rates. RESULTS: Between 1963 and 2002, 1,161 cases of pregnancy-associated breast cancer among a total of 16,620 breast cancers were identified in women aged 15 to 44 years. The incidence of pregnancy-associated breast cancer increased from 16.0 to 37.4 per 100,000 deliveries comparing the first and last calendar periods under study. During pregnancy, the overall incidence was 2.4 per 100,000 deliveries; the incidence during the first and second year after delivery was 10.6 and 15.0 per 100,000 deliveries, respectively. Fewer pregnancy-associated breast cancers than expected were diagnosed during pregnancy and the first 6 months after delivery. Thereafter, there was no difference between observed compared with expected number of breast cancers. CONCLUSION: The incidence of pregnancy-associated breast cancer increased during the study period, partly caused by a trend of postponement of childbearing to an older age. The present findings suggest that breast cancer is underdiagnosed during pregnancy and lactation. LEVEL OF EVIDENCE: III